According to the latest report by IMARC Group, titled “North America Travel Vaccines Market Report by Composition (Mono Vaccines, Combination Vaccines), Disease (Hepatitis A, DPT, Yellow Fever, Typhoid, Hepatitis B, Measles and Mumps, Rabies, Meningococcal, Varicella, Japanese Encephalitis, and Others), and Country 2024-2032,” the North America travel vaccines market size reached US$ 1.9 Billion in 2023. Travel Vaccines are specialized immunizations designed to protect individuals from infectious diseases that may be prevalent in foreign countries or regions. When people travel internationally, they may encounter health risks that differ from those in their home country. Travel vaccines offer crucial protection by stimulating the body's immune system to produce antibodies against specific diseases, preventing infection and potential health complications. These vaccines are tailored to address the unique risks associated with different travel destinations, considering factors such as the traveler's health status, destination, and stay duration. The primary objective of travel vaccines is to safeguard travelers' health and well-being during their journeys and prevent the spread of infectious diseases across borders.
North America Travel Vaccines Market Trends:
The rising awareness among travelers about the importance of pre-travel health preparations as more individuals embark on international trips for leisure, business, or educational purpose are some of the major factors driving the market growth. Travel vaccines safeguard individuals’ health, thus ensuring a seamless travel experience. Additionally, the increasing cross-border trade in North America as companies expand their operations internationally, propelling companies to implement pre-travel health programs recommending employees to get appropriate travel vaccines, is positively impacting the market growth. Moreover, the rising need for specialized vaccines catering to specific travel destinations has encouraged pharmaceutical companies to invest in research and development (R&D) efforts to create vaccines that meet these concerns, further offering comprehensive protection and boosting travelers' confidence. Furthermore, rapid advancements in medical technology and vaccine development leading to the introduction of combination vaccines that offer protection against multiple diseases with a single shot, streamlining the vaccination process for travelers, is favoring the market growth. Besides this, the increasing prevalence of private travel clinics and specialized travel healthcare providers in the region offering personalized pre-travel consultations, where healthcare professionals assess travelers' health risks and recommend appropriate vaccines and preventive measures, is providing remunerative growth opportunities. Looking forward, the market value is projected to reach US$ 3.2 Billion by 2032, expanding at a CAGR of 5.7% during 2024-2032.
Market Summary:
- Based on the composition, the market has been segmented as mono and combination vaccines.
- On the basis of the disease, the market has been divided into hepatitis A, DPT, yellow fever, typhoid, hepatitis B, measles and mumps, rabies, meningococcal, varicella, Japanese encephalitis, and others.
- Region-wise, the market has been segmented into the United States, Canada, and Mexico.
- The competitive landscape of the market has also been examined along with the profiles of the key players.
Report Scope:
Report Features |
Details |
Base Year of the Analysis |
2023 |
Historical Period |
2018-2023 |
Forecast Period |
2024-2032 |
Units |
US$ Billion |
Segment Coverage |
Composition, Disease, Country |
Countries Covered |
United States, Canada, Mexico |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 3699
Five User License: US$ 4699
Corporate License: US$ 5699 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800